Showing results (1681-1690 of 1,849) with videos related to

Sort By:
Pageof 185
Reproductive Medicine and Biology|June 10, 2024
Effect of single versus grouped culture of human cumulus-oocyte complexes in PCOS women treated with biphasic in vitro maturation: A sibling oocyte pilot studyHuy H Pham, Anh H Le, Tri C Nguyen, et al.
Molecular Psychiatry|February 14, 2019
Towards precision medicine for pain: diagnostic biomarkers and repurposed drugsA B Niculescu, H Le-Niculescu, D F Levey, et al.
Osteoarthritis and Cartilage|June 1, 2018
Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre projectD Braconi, D Giustarini, B Marzocchi, et al.
Stem Cells Translational Medicine|April 27, 2026
A selection model for umbilical cord blood units with high isolation yield of total nucleated and CD34+ cellsVuong M Pham, Hung V Nguyen, Qui T Dang, et al.
Infectious Diseases and Therapy|April 16, 2026
Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart ReviewNurilign Ahmed, Van M Nguyen, Anh C Pham, et al.
International Journal of Pharmaceutics|November 1, 2025
Expert opinion on extrusion-based pharmaceutical 3D printing from the European Society of Hospital Pharmaceutical Technology (GERPAC)Aisha A Ahmed, Kirsten J M Schimmel, Marija Tubic-Grozdanis, et al.
The Journal of Trauma and Acute Care Surgery|May 21, 2021
P-selectin antibody treatment after blunt thoracic trauma prevents early pulmonary arterial thrombosis without changes in viscoelastic measurements of coagulationLinda M Schutzman, Rob R Rigor, Yung-Ling J Lin, et al.
Phytochemistry|April 21, 2001
A pregnane steroid from Aglaia lawii and structure confirmation of cabraleadiol monoacetate by X-ray crystallographyS X Qiu, V H Nguyen, T X Le, et al.
Nature|April 6, 1995
Anti-inflammatory properties of a platelet-activating factor acetylhydrolaseL W Tjoelker, C Wilder, C Eberhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
Pageof 185